Cover Image

Update breast cancer 2022: Part 2: Advanced stage breast cancer

<p>For patients with advanced breast cancer, several novel therapies have emerged in recent years, including CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors, alpelisib, tucatinib and trastuzumab-deruxtecan, and sacituzumab-govitecan, which have transformed and expanded the the...

Full description

Saved in:
Bibliographic Details
Main Authors: Müller, Volkmar (Author) , Welslau, Manfred (Author) , Lüftner, Diana (Author) , Schütz, Florian (Author) , Stickeler, Elmar (Author) , Fasching, Peter A. (Author) , Janni, Wolfgang (Author) , Thomssen, Christoph (Author) , Witzel, Isabell (Author) , Fehm, Tanja (Author) , Belleville, Erik (Author) , Bader, Simon (Author) , Seitz, Katharina (Author) , Untch, Michael (Author) , Thill, Marc (Author) , Tesch, Hans (Author) , Ditsch, Nina (Author) , Lux, Michael P. (Author) , Aktas, Bahriye (Author) , Banys-Paluchowski, Maggie (Author) , Schneeweiss, Andreas (Author) , Harbeck, Nadia (Author) , Würstlein, Rachel (Author) , Hartkopf, Andreas D. (Author) , Kolberg, Hans-Christian (Author) , Wöckel, Achim (Author)
Format: Article (Journal)
Language:English
Published: 03. Juni 2022
In: Geburtshilfe und Frauenheilkunde
Year: 2022, Volume: 82, Issue: 6, Pages: 590-600
ISSN:1438-8804
DOI:10.1055/a-1811-6148
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1811-6148
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1811-6148
Get full text
Author Notes:Volkmar Müller, Manfred Welslau, Diana Lüftner, Florian Schütz, Elmar Stickeler, Peter A. Fasching, Wolfgang Janni, Christoph Thomssen, Isabell Witzel, Tanja N. Fehm, Erik Belleville, Simon Bader, Katharina Seitz, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P. Lux, Bahriye Aktas, Maggie Banys-Paluchowski, Andreas Schneeweiss, Nadia Harbeck, Rachel Würstlein, Andreas D. Hartkopf, Hans-Christian Kolberg, Achim Wöckel
Description
Summary:<p>For patients with advanced breast cancer, several novel therapies have emerged in recent years, including CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors, alpelisib, tucatinib and trastuzumab-deruxtecan, and sacituzumab-govitecan, which have transformed and expanded the therapeutic landscape for patients with advanced breast cancer. Some of these substances have now been approved for use in the early stages of the disease, or are expected to be approved in the near future, so the therapeutic landscape will change once again. Therefore, current scientific efforts are focused on the introduction of new substances and understanding their mechanisms of progression and efficacy. This review summarizes recent developments with reference to recent publications and conferences. Findings on the treatment of patients with HER2-positive breast cancer and brain metastases are presented, as are a number of studies looking at biomarkers in patients with HER2-negative, hormone receptor-positive breast cancer. In particular, the introduction of oral selective estrogen receptor degraders provides new opportunities to establish biomarker-based therapy. Molecular diagnostics is establishing itself as a diagnostic marker and parameter of progression.</p>
Item Description:Gesehen am 19.01.2023
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-1811-6148

Similar Items